These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 14671620

  • 1. Refractory cold agglutinin-immunohaemolytic anaemia associated to marginal zone lymphoma responding to rituximab.
    Petit J, Clavo M, de Sevilla AF, González-Barca E, Domingo-Doménech E, Grañena A.
    Hematol J; 2003; 4(6):450-1. PubMed ID: 14671620
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy.
    Mori A, Tamaru J, Sumi H, Kondo H.
    Eur J Haematol; 2002 Apr; 68(4):243-6. PubMed ID: 12071942
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma.
    Lossos IS, Morgensztern D, Blaya M, Alencar A, Pereira D, Rosenblatt J.
    Leuk Lymphoma; 2007 Aug; 48(8):1630-2. PubMed ID: 17701596
    [No Abstract] [Full Text] [Related]

  • 8. Severe anemia caused by combination of autoimmune hemolysis, pure red cell aplasia and massive bone marrow infiltration in an elderly patient with chronic lymphocytic leukemia: successful treatment with rituximab.
    Smolej L, Belada D, Cermanová M, Maisnar V, Lunáková E.
    Leuk Res; 2010 May; 34(5):e140-1. PubMed ID: 20053448
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Efficacity of rituximab in hemolytic anemia with cold autoantibodies case].
    Sekkach Y, Hammi S, Elqatni M, Fatihi J, Elomri N, Mekouar F, Badaoui M, Jira M, Smaali J, El Khattabi A, Amezyane T, Abouzahir A, Ghafir D.
    Ann Pharm Fr; 2011 Jul; 69(4):205-8. PubMed ID: 21840439
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. About the old and the new: gallium-67 scintigraphy to rituximab for lymphoma.
    DeNardo GL.
    Cancer Biother Radiopharm; 1999 Aug; 14(4):235-6. PubMed ID: 10850308
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Remission of severe cold agglutinin disease after Rituximab therapy.
    Layios N, Van Den Neste E, Jost E, Deneys V, Scheiff JM, Ferrant A.
    Leukemia; 2001 Jan; 15(1):187-8. PubMed ID: 11243390
    [No Abstract] [Full Text] [Related]

  • 17. Rituximab monotherapy for splenic marginal zone lymphoma.
    Bennett M, Sharma K, Yegena S, Gavish I, Dave HP, Schechter GP.
    Haematologica; 2005 Jun; 90(6):856-8. PubMed ID: 15951303
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Syndrome of inappropriate antidiuretic hormone secretion due to marginal zone lymphoma: responding to rituximab.
    Bockorny B, Dasanu CA.
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):220-2. PubMed ID: 22578816
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.